Expanding Treatment Options for Aggressive Breast Cancer
The FDA approved the use of an immunotherapeutic in combination with chemotherapy to treat certain patients with triple-negative breast cancer.
Progress Against Cancer
The FDA approved the use of an immunotherapeutic in combination with chemotherapy to treat certain patients with triple-negative breast cancer.
Steroid used to prevent swelling in the brains of patients with glioblastoma may have “detrimental effect” on treatment with immune checkpoint inhibitors.
The FDA granted approval to expand the use of a minimally invasive biomarker test to identify certain patients with ovarian, lung, breast, or prostate cancer eligible for treatment with specific molecularly targeted therapeutics.
An attempt to learn why some patients have an exceptional response to cancer treatment, and more news of the week from Cancer Today.
Socioeconomic factors and racism can lead to poorer health outcomes for Black Americans.
Artificial intelligence may help predict response to immunotherapy among patients with metastatic melanoma, study reports.
A survey indicates that the pandemic is reducing cancer patients’ willingness to enroll in cancer clinical trials, and more news of the week from Cancer Today.
Disproportionate share of the burden of premature cancer deaths in the United States falls on racial and ethnic minorities and on younger people. More than 4 million potential years of life were lost to...
nce thought sterile, lungs can harbor microbes that may affect lung cancer pathogenesis and prognosis.
A new study indicates that liquid biopsy may return results quicker than tissue biopsy.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More